Literature DB >> 33031602

Angiotensin-converting enzyme 2: A protective factor in regulating disease virulence of SARS-COV-2.

Vignesh Mariappan1, Rao S R2, Agieshkumar Balakrishna Pillai1.   

Abstract

Novel SARS-CoV-2 named due to its close homology with severe acute respiratory syndrome coronavirus (SARS-CoV) is the etiologic agent for the ongoing pandemic outbreak causing loss of life and severe economic burden globally. The virus is believed to be evolved in a recombined form of bat and animal coronavirus with the capacity to infect human host using the ACE2 receptors as an entry point. Though the disease pathogenesis is not elucidated completely, the virus-mediated host response retains a similar pattern to that of previous SARS-CoV. Based on the available trend it is assumed that pediatric groups are less susceptible to the coronavirus. Understanding the possible mechanism that protects the children from hyper-inflammatory or disease severity could lead to better treatment modalities. In the present review, we have discussed the significance of age and sex-dependent pattern of ACE2 receptor expression and ACE2 variants in the immune protective mechanism of the disease virulence. We have also added a brief note on the importance of sex hormones in the pathogenesis of ACE2 mediated SARS-CoV2 infection.
© 2020 International Union of Biochemistry and Molecular Biology.

Entities:  

Keywords:  ACE2; ACE2 polymorphism; COVID19; SARS-CoV-2; TMPRSS2

Mesh:

Substances:

Year:  2020        PMID: 33031602     DOI: 10.1002/iub.2391

Source DB:  PubMed          Journal:  IUBMB Life        ISSN: 1521-6543            Impact factor:   3.885


  9 in total

1.  mRNA expression of the severe acute respiratory syndrome-coronavirus 2 angiotensin-converting enzyme 2 receptor in the lung tissue of Wistar rats according to age.

Authors:  Hazem Almhanna; Nabeel Abd Murad Al-Mamoori; Hassan Hachim Naser
Journal:  Vet World       Date:  2022-02-24

2.  Early shedding of membrane-bounded ACE2 could be an indicator for disease severity in SARS-CoV-2.

Authors:  Vignesh Mariappan; Pajanivel Ranganadin; Lokesh Shanmugam; S R Rao; Agieshkumar Balakrishna Pillai
Journal:  Biochimie       Date:  2022-06-17       Impact factor: 4.372

Review 3.  ACE2: the molecular doorway to SARS-CoV-2.

Authors:  Miriam Marlene Medina-Enríquez; Sandra Lopez-León; José Alberto Carlos-Escalante; Zuleika Aponte-Torres; Angelica Cuapio; Talia Wegman-Ostrosky
Journal:  Cell Biosci       Date:  2020-12-30       Impact factor: 7.133

Review 4.  Mutations and polymorphisms in genes involved in the infections by covid 19: a review.

Authors:  Ait Boujmia Oum Kaltoum
Journal:  Gene Rep       Date:  2021-02-25

5.  A systematic review of Vaccine Breakthrough Infections by SARS-CoV-2 Delta Variant.

Authors:  Mengxin Zhang; Ying Liang; Dongsheng Yu; Bang Du; Weyland Cheng; Lifeng Li; Zhidan Yu; Shuying Luo; Yaodong Zhang; Huanmin Wang; Xianwei Zhang; Wancun Zhang
Journal:  Int J Biol Sci       Date:  2022-01-01       Impact factor: 6.580

Review 6.  Anticipated pharmacological role of Aviptadil on COVID-19.

Authors:  Tuhin Mukherjee; Tapan Behl; Sanchay Sharma; Aayush Sehgal; Sukhbir Singh; Neelam Sharma; Bijo Mathew; Jasleen Kaur; Ratandeep Kaur; Mayukh Das; Lotfi Aleya; Simona Bungau
Journal:  Environ Sci Pollut Res Int       Date:  2021-11-30       Impact factor: 5.190

Review 7.  Role of genetic variants and host polymorphisms on COVID-19: From viral entrance mechanisms to immunological reactions.

Authors:  Abolfazl Adli; Mandana Rahimi; Reza Khodaie; Niloofar Hashemzaei; Sayed M Hosseini
Journal:  J Med Virol       Date:  2022-02-08       Impact factor: 20.693

Review 8.  Restoration of vascular endothelial integrity by mesenchymal stromal/stem cells in debilitating virus diseases.

Authors:  Agieshkumar Balakrishna Pillai; Vignesh Mariappan; Aashika Raagavi JeanPierre; S R Rao
Journal:  Hum Cell       Date:  2022-09-06       Impact factor: 4.374

9.  Potential activity of Linezolid against SARS-CoV-2 using electronic and molecular docking study.

Authors:  Nelson H Morgon; Giulia S Grandini; Maurício I Yoguim; Caio M Porto; Lucas C Santana; Srijit Biswas; Aguinaldo R de Souza
Journal:  J Mol Model       Date:  2021-07-08       Impact factor: 1.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.